TY - JOUR
T1 - Drug delivery system targeting advanced hepatocellular carcinoma
T2 - Current and future
AU - Zhang, Xue
AU - Ng, Huei Leng Helena
AU - LYU, Aiping
AU - Lin, Congcong
AU - ZHOU, Limin
AU - Lin, Ge
AU - Zhang, Yanbo
AU - YANG, Zhijun
AU - ZHANG, Hong Qi
N1 - Funding Information:
We gratefully acknowledge funding for this work provided by the Hong Kong Baptist University Faculty Research Grant ( FRG2/14-15/082 ), and the University Grants Committee of Hong Kong for the General Research Fund ( HKBU 12102514 ).
PY - 2016/5
Y1 - 2016/5
N2 - Hepatocellular carcinoma (HCC) has a fairly high morbidity and is notoriously difficult to treat due to long latent period before detection, multidrug resistance and severe drug-related adverse effects from chemotherapy. Targeted drug delivery systems (DDS) that can selectively deliver therapeutic drugs into tumor sites have demonstrated a great potential in cancer treatment, which could be utilized to resolve the limitations of conventional chemotherapy. Numerous preclinical studies of DDS have been published, but targeted DDS for HCC has yet to be made for practical clinical use. Since rational targeted DDS design should take cancer-specific properties into consideration, we have reviewed the biological and physicochemical properties of HCC extensively to provide a comprehensive understanding on HCC, and recent DDS studies on HCC, aiming to find some potential targeted DDSs for HCC treatment and a meaningful platform for further development of HCC treatments.
AB - Hepatocellular carcinoma (HCC) has a fairly high morbidity and is notoriously difficult to treat due to long latent period before detection, multidrug resistance and severe drug-related adverse effects from chemotherapy. Targeted drug delivery systems (DDS) that can selectively deliver therapeutic drugs into tumor sites have demonstrated a great potential in cancer treatment, which could be utilized to resolve the limitations of conventional chemotherapy. Numerous preclinical studies of DDS have been published, but targeted DDS for HCC has yet to be made for practical clinical use. Since rational targeted DDS design should take cancer-specific properties into consideration, we have reviewed the biological and physicochemical properties of HCC extensively to provide a comprehensive understanding on HCC, and recent DDS studies on HCC, aiming to find some potential targeted DDSs for HCC treatment and a meaningful platform for further development of HCC treatments.
KW - Advanced hepatocellular carcinoma
KW - Liver cancer
KW - Nanomedicine
KW - Targeted drug delivery systems
UR - http://www.scopus.com/inward/record.url?scp=84960897041&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2015.12.381
DO - 10.1016/j.nano.2015.12.381
M3 - Review article
C2 - 26772424
AN - SCOPUS:84960897041
SN - 1549-9634
VL - 12
SP - 853
EP - 869
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
IS - 4
ER -